c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli

Oncogene. 2001 Sep 20;20(42):6084-94. doi: 10.1038/sj.onc.1204827.

Abstract

In addition to c-myc rearrangement, over 50% of Burkitt's lymphoma cases present clustered mutations in exon 2, where many of the functional activities of c-Myc protein are based. This report describes the functional consequences induced by tumour-derived c-myc mutations located in c-myc box II. Two mutated alleles were studied, focusing on the P138C mutation, and compared to wild-type c-myc. The c-Myc transformation, transactivation and apoptosis activities were explored based on cells over-expressing c-Myc. While the transcriptional activation activity was not affected, our experiments exploring the anchorage-independent growth capacity of c-Myc-transfected Rat1a cells showed that c-Myc box II mutants were less potent than wild-type c-Myc in promoting cell transformation. Considering the possibility that these mutations could be interfering with the ability of c-Myc to promote apoptosis, we tested c-Myc-transfected Rat1a fibroblasts under several conditions: serum deprivation-, staurosporine- and TNFalpha-induced cell death. Interestingly, the mutated alleles were characterized by an overall decrease in ability to mediate apoptosis. Our study indicates that point mutations located in c-Myc box II can decrease the ability of the protein to promote both transformation and apoptosis without modifying its transactivating activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Animals
  • Apoptosis*
  • Burkitt Lymphoma / genetics*
  • Burkitt Lymphoma / pathology
  • Cell Line
  • Cell Transformation, Neoplastic*
  • Conserved Sequence
  • Phenotype
  • Point Mutation*
  • Proto-Oncogene Proteins c-myc / genetics*
  • Proto-Oncogene Proteins c-myc / physiology*
  • Rats
  • Receptors, Estrogen / agonists
  • Receptors, Estrogen / genetics
  • Receptors, Estrogen / metabolism
  • Recombinant Fusion Proteins / metabolism
  • Staurosporine / pharmacology
  • Tamoxifen / analogs & derivatives*
  • Tamoxifen / pharmacology
  • Trans-Activators / genetics
  • Trans-Activators / physiology
  • Transfection
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Proto-Oncogene Proteins c-myc
  • Receptors, Estrogen
  • Recombinant Fusion Proteins
  • Trans-Activators
  • Tumor Necrosis Factor-alpha
  • Tamoxifen
  • afimoxifene
  • Staurosporine